The NF-κB pathway is associated with poor prognosis and response to drug treatment, and represents an emerging drug target in CLL.17,40–44 The mechanism underlying high UGT2B17 expression in B-cells remains to be fully explored. Here, UGT2B17 is linked to B-cell chronic lymphocytic leukemia.